ScreenerHero
ETONEton Pharmaceuticals, Inc.
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · etonpharma.com
61.03USD-0.73%Mkt Cap: 1.76B $P/E: 157.64

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap1.76B $
Enterprise Value1.71B $
Revenue (TTM)105.59M $
Gross Profit42.74M $
Net Income (TTM)-4.60M $
Revenue/Share3.884 USD
Last Price61.03 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees44
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)157.64
P/E (Forward)23.22
PEG—
EV/EBITDA68.11
EV/Revenue16.24
P/S16.22
P/B36.38
EPS (TTM)0.38
EPS (Forward)2.58
52W Range
14.2794% of range63.83
52W High63.83 USD
52W Low14.27 USD
Profitability
Gross Margin53.46%
Oper. Margin35.77%
EBITDA Margin23.84%
Profit Margin-5.75%
ROE-17.59%
ROA-4.99%
Growth
Revenue Growth98.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF10.52M $
CapEx (TTM)333.00K $
FCF Margin6.23%
FCF Yield0.37%
Net Debt2.38M $
Net Debt/EBITDA0.09
Balance Sheet
Debt/Equity1.19
Current Ratio1.52
Quick Ratio1.15
Book Value/Sh1.647 USD
Cash/Share0.9390 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)71.00 USD
Upside (mean)+16.3%
Target Range68.00 USD – 76.00 USD
$68.00+16.3% to mean$76.00
# Analysts4
Ownership
Shares Out.28.58M
Float22.24M
Insiders5.17%
Institutions70.17%
Short Interest
Short Ratio2.5d
Short % Float6.74%
Short % Out.4.79%
Shares Short1.31M
Short (prev mo.)1.45M
Technical
SMA 5041.38 (+47.5%)
SMA 20025.86 (+136.0%)
Beta0.87
S&P 52W Chg18.16%
Avg Vol (30d)593.37K
Avg Vol (10d)806.22K
Technical Indicators
RSI (14)77.4
MACD4.2618
MACD Signal2.8266
MACD Hist.+1.4352
BB Upper59.60 USD
BB Middle47.04 USD
BB Lower34.47 USD
BB Width53.43%
ATR (14)3.775 USD
Vol Ratio (20d)0.96x